Overview: The first of 3,000 Actos lawsuits is going to trial, with jury selection beginning today in Los Angeles state court. The case being tried is Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court (Los Angeles); Plaintiff Jack Cooper alleges that Takeda’s diabetes medication Actos caused him to develop bladder cancer. The lawsuit alleges that Takeda failed to warn about the risks of taking Actos even though they were aware that it could cause bladder cancer prior to approval.
- The first Actos trial begins today in California state court; jury selection is slated to begin
- There are 3,000 Actos lawsuits alleging Actos caused bladder cancer and other illnesses
- The FDA has warned that taking Actos for one year or more could raise the risk of bladder cancer
Product: Actos (pioglitazone)
Manufacturer: Takeda Pharmaceutical
Side Effects & Complications
- Bladder cancer
- Heart attacks
- Congestive heart failure
Jury selection is slated to begin today in Los Angeles state court, according to Bloomberg. The lawsuit going to trial was filed on behalf of Jack Cooper, a former cable splicer who took Actos for over two years before being diagnosed with bladder cancer in November 2011. The lawsuit alleges that Actos caused the bladder cancer and that Takeda failed to warn about the risks even though they were aware of them. Coopers claims that Takeda resisted the FDA’s request to add a bladder cancer warning to Actos for years in order to boost sales. Actos was once the best-selling diabetes drug in the world; sales peaked in the year ended March 2011 at $4.5 billion, accounting for 27 percent of Takeda’s revenue at the time.
Bloomberg reports that there are 3,000 Actos lawsuits alleging bladder cancer and other complications. Many cases have been filed in federal court as part of the Actos multidistrict litigation entitled In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299). Judge Rebecca Doherty is presiding over the litigation and Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiff’s Steering Committee.
Actos Bladder Cancer
Actos was approved in 1999 to treat patients with Type 2 diabetes. The drug is part of the thiazolidinedione class, which also includes the medication Avandia. Sales of Actos increased significantly when Avandia was linked to an increased risk of heart attacks. New evidence linking the drug to bladder cancer, however, has raised questions about its safety profile. The FDA has warned that taking Actos for more than a year could significantly raise the risk of bladder cancer. In June 2011, the drug was pulled off the shelves in France and Germany due to its association with bladder cancer.